Drug
Asp2767
Asp2767: highest development phase Phase 1/2, developed by Astellas. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| ASP2767 NCT07770685 | Phase 1/2 | Glaucoma |
Latest
No recent events.
Follow Asp2767 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.